A 29-MRNA HOST RESPONSE WHOLE-BLOOD SIGNATURE IMPROVES PREDICTION OF 28-DAY MORTALITY AND 7-DAY INTENSIVE CARE UNIT CARE IN ADULTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH SUSPECTED ACUTE INFECTION AND/OR SEPSIS.

"James W. Wacker, Florian Uhle, Oliver Liesenfeld, and Timothy E. Sweeney are employees and stock option holders of Inflammatix Inc. Catherine A. Hogan is a consultant for Inflammatix. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc., and B·R·A·H·M·S GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc., Abbott CH, bioMérieux Inc., Novartis, InflaRx GmbH, UCB, Sobi, and XBiotech Inc; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis), and by the Horizon Europe grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not declare any conflict of interest."

"This study was supported in part by Inflammatix Inc. and in part by the Hellenic Institute for the Study of Sepsis."